Savara Inc (NASDAQ:SVRA) Brief Interest Update
Savara Inc. (NASDAQ: SVRA – Get a rating) saw a sharp decline in short-term interest in August. As of August 15, there was short interest totaling 544,600 shares, down 20.6% from the July 31 total of 686,100 shares. Based on an average daily trading volume of 172,100 shares, the short interest ratio is currently 3.2 days. Currently, 0.8% of the company’s shares are sold short.
Savara share performance
Shares of SVRA opened at $1.43 on Friday. The stock has a market capitalization of $163.08 million, a P/E ratio of -5.72 and a beta of 0.90. Savara has a 1-year low of $1.02 and a 1-year high of $1.91. The company’s fifty-day moving average is $1.66 and its two-hundred-day moving average is $1.39. The company has a debt ratio of 0.20, a quick ratio of 39.23 and a current ratio of 39.23.
Insider Trading at Savara
In related news, the director David A. Ramsay bought 21,094 shares of the company in a trade on Tuesday, June 21. The shares were acquired at an average price of $1.38 per share, for a total transaction of $29,109.72. Following the purchase, the director now owns 1,562,142 shares of the company, valued at approximately $2,155,755.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, accessible via the SEC website. In other Savara news, Director David A. Ramsay purchased 39,906 Savara shares in a trade dated Friday, June 17. The shares were acquired at an average cost of $1.33 per share, for a total transaction of $53,074.98. Following completion of the transaction, the administrator now directly owns 1,541,048 shares of the company, valued at $2,049,593.84. The purchase was disclosed in a filing with the SEC, accessible via this hyperlink. Additionally, director David A. Ramsay acquired 21,094 shares of the company in a transaction that took place on Tuesday, June 21. The shares were purchased at an average price of $1.38 per share, with a total value of $29,109.72. Following completion of the transaction, the administrator now owns 1,562,142 shares of the company, valued at approximately $2,155,755.96. Disclosure of this purchase can be found here. Company insiders hold 3.57% of the company’s shares.
Institutional entries and exits
Institutional investors and hedge funds have recently changed their stock holdings. Renaissance Technologies LLC increased its stake in Savara by 235.3% during the second quarter. Renaissance Technologies LLC now owns 56,000 shares of the company worth $85,000 after purchasing an additional 39,300 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in Savara by 6.9% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 144,432 shares of the company valued at $220,000 after acquiring 9,363 additional shares last quarter. Millennium Management LLC increased its stake in Savara by 12.3% during the second quarter. Millennium Management LLC now owns 156,314 shares of the company valued at $238,000 after acquiring an additional 17,093 shares in the last quarter. State Street Corp increased its stake in Savara shares by 12.4% in Q1. State Street Corp now owns 271,611 shares of the company valued at $356,000 after buying an additional 30,062 shares last quarter. Finally, Sio Capital Management LLC purchased a new equity stake in Savara in Q4 valued at approximately $807,000. Institutional investors and hedge funds own 71.64% of the company’s shares.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in patients with cystic fibrosis.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Savara, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market goes viral…and Savara wasn’t on the list.
While Savara currently has an “N/A” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here